Bain Capital Life Sciences Investors, LLC

Person Signing this Report on Behalf of Reporting Manager:

Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP and (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general parter of Bain Capital Life Sciences Fund II, L.P. Bain Capital Life Sciences Investors, LLC governs the investment strategy and decision-making process with respect to investments held by BCIP Life Sciences Associates, LP.The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on March 17, 2021 and reflect the exercise of securities exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise. As of June 30, 2022, such persons held an aggregate of 6,913,208 shares of SVRA common stock.The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS" ) included on the Information Table are as reported on Amendment No. 1 to the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on February 14, 2022 and reflect the exercise of securities exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise. As of June 30, 2022, such persons held an aggregate of 5,504,661 shares of SYRS common stock.

Other Included Managers (6):